"Recombinant Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins prepared by recombinant DNA technology.
| Descriptor ID |
D011994
|
| MeSH Number(s) |
D12.776.828
|
| Concept/Terms |
Recombinant Proteins- Recombinant Proteins
- Proteins, Recombinant
- Proteins, Biosynthetic
- Biosynthetic Proteins
Proteins, Recombinant DNA- Proteins, Recombinant DNA
- DNA Proteins, Recombinant
- Recombinant DNA Proteins
- DNA Recombinant Proteins
- Proteins, DNA Recombinant
- Recombinant Proteins, DNA
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Proteins".
This graph shows the total number of publications written about "Recombinant Proteins" by people in this website by year, and whether "Recombinant Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 3 | 5 |
| 2015 | 0 | 2 | 2 |
| 2016 | 3 | 3 | 6 |
| 2017 | 0 | 4 | 4 |
| 2018 | 2 | 2 | 4 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Proteins" by people in Profiles.
-
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. 2024 Mar; 30(2):257-266.
-
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat Commun. 2023 07 19; 14(1):4347.
-
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931.
-
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov; 27(6):911-920.
-
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
-
Hepatitis C infection at a tertiary hospital in South Africa: Clinical presentation, non-invasive assessment of liver fibrosis, and response to therapy. S Afr Med J. 2020 Aug 31; 110(9):920-925.
-
Effects of Serelaxin in Patients with Acute Heart Failure. N Engl J Med. 2019 08 22; 381(8):716-726.
-
N-glycosylation and homodimeric folding significantly enhance the immunoreactivity of Mycobacterium tuberculosis virulence factor CFP32 when produced in the yeast Pichia pastoris. Biochem Biophys Res Commun. 2019 08 27; 516(3):845-850.
-
Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials. Haemophilia. 2018 Nov; 24(6):911-920.
-
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia. 2018 May; 24(3):376-384.